BeStock  

Aquestive Therapeutics AQST

US equityMarket cap rank #3651Drug Manufacturers - Specialty & Generic
$3.46 −$0.25 (-6.61%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.52 +1.73%
Open$3.62
Prev close$3.71
Day range$3.41 – $3.65
Volume3.36M
Market cap$434.88M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$7.56M-41.0% YoY
Operating profit-$14.47M-26.0% YoY
Net profit-$16.50M-6.8% YoY
Diluted EPS-$0.13+7.1% YoY
Free cash flow-$7.63M+40.8% YoY
Operating cash flow-$7.05M

Revenue, last 8 quarters

$11.9MDec '24$8.7MMar '25$10.0MJun '25$12.8MSep '25$13.0MDec '25$14.4MMar '26$13.8MJun '26$7.6MSep '26

Net profit, last 8 quarters

$-17.1MDec '24$-22.9MMar '25$-13.5MJun '25$-15.4MSep '25$-31.9MDec '25$-8.1MMar '26$-22.9MJun '26$-16.5MSep '26

Diluted EPS by quarter

-0.19Dec '24-0.24Mar '25-0.14Jun '25-0.14Sep '25-0.26Dec '25-0.07Mar '26-0.18Jun '26-0.13Sep '26

Free cash flow by quarter

$-6.5MDec '24$-23.5MMar '25$-8.0MJun '25$-12.9MSep '25$-8.6MDec '25$-14.9MMar '26$-9.7MJun '26$-7.6MSep '26

Annual revenue

$45.8MFY20$50.8MFY21$47.7MFY22$50.6MFY23$57.6MFY24$44.5MFY25

Profitability & balance sheet

Gross margin65.3%
Operating margin-114.1%
Net margin-162.3%
Return on assets-56.0%
Current ratio6.12
Liabilities / assets159.4%
Cash & investments$90.35M
Total debt$58.15M
Net cash (debt)$32.20M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $7.56M $13.82M $14.45M $44.55M $13.02M
Total Operating Revenue $7.56M $13.82M $14.45M $44.55M $13.02M
Cost of Revenue $3.61M $4.02M $3.47M $18.56M $5.84M
Gross Profit $3.95M $9.80M $10.98M $25.99M $7.18M
Operating Expense $18.42M $18.03M $15.18M $97.04M $36.02M
Selling and Admin Expenses $14.17M $14.06M $10.98M $79.85M $32.82M
Research & Development $4.25M $3.96M $4.20M $17.19M $3.20M
Operating Profit -$14.47M -$8.22M -$4.20M -$71.05M -$28.84M
Net Non-Operating Interest Income (Expense) -$2.03M -$2.96M -$3.85M -$12.73M -$3.02M
Non-Operating Interest Income $853,000.00 $882,000.00 $83,000.00 $4.37M $1.25M
Non-Operating Interest Expense $2.88M $3.84M $3.94M $17.10M $4.27M
Special Income (Charges) $0.00 -$11.68M – – –
Pretax Profit -$16.50M -$22.86M -$8.06M -$83.78M -$31.86M
Net Profit -$16.50M -$22.86M -$8.06M -$83.78M -$31.86M
Profit from Continuing Operations -$16.50M -$22.86M -$8.06M -$83.78M -$31.86M
Net Income to Parent Company -$16.50M -$22.86M -$8.06M -$83.78M -$31.86M
Net Income to Common Stockholders -$16.50M -$22.86M -$8.06M -$83.78M -$31.86M
Basic EPS -$0.13 -$0.18 -$0.07 -$0.78 -$0.26
Diluted EPS -$0.13 -$0.18 -$0.07 -$0.78 -$0.26
Other Income (Expense) – -$11.68M – – –
-Less:Other Special Charges – $11.68M – – –
Tax – – – $0.00 –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $119.33M $132.10M $141.13M $160.43M $160.43M
Total Current Assets $105.83M $118.49M $130.18M $149.27M $149.27M
Cash and Cash Equivalents & Short-Term Investments $90.35M $98.49M $110.73M $121.17M $121.17M
-Cash and Cash Equivalents $90.35M $98.49M $110.73M $121.17M $121.17M
Receivables $5.25M $9.33M $6.87M $17.76M $17.76M
-Accounts Receivable $3.70M $7.72M $5.26M $8.01M $8.01M
-Other Receivables $1.55M $1.61M $1.61M $10.33M $10.33M
-Receivables Adjustments Allowances $0.00 $0.00 $0.00 -$582,000.00 -$582,000.00
Inventory $7.31M $7.37M $8.07M $6.17M $6.17M
Other Current Assets $2.91M $3.31M $4.52M $4.17M $4.17M
Total Non-Current Assets $13.50M $13.61M $10.94M $11.16M $11.16M
Net PPE $11.81M $11.91M $8.31M $8.51M $8.51M
-Gross PPE $51.33M $56.17M $52.43M $52.54M $52.54M
-Accumulated Depreciation -$39.52M -$44.26M -$44.13M -$44.02M -$44.02M
Non Current Accounts Receivables $1.00M $1.00M $2.00M $2.00M $2.00M
Other Non-Current Assets $693,000.00 $701,000.00 $635,000.00 $642,000.00 $642,000.00
Total Liabilities $190.15M $188.69M $175.18M $194.09M $194.09M
Total Current Liabilities $17.30M $16.48M $31.75M $47.61M $47.61M
Payables $9.22M $9.29M $12.30M $30.21M $30.21M
-Accounts Payable $8.82M $8.97M $11.89M $29.86M $29.86M
-Total Tax Payable $404,000.00 $328,000.00 $408,000.00 $349,000.00 $349,000.00
Current Accrued Expenses $988,000.00 $968,000.00 $972,000.00 $973,000.00 $973,000.00
Short-Term Debt and Capital Lease Obligation $656,000.00 $852,000.00 $14.32M $10.63M $10.63M
-Current Debt $33,000.00 $32,000.00 $13.66M $9.99M $9.99M
-Current Capital Lease Obligation $623,000.00 $820,000.00 $662,000.00 $631,000.00 $631,000.00
Current Deferred Liabilities $1.09M $1.09M $1.09M $1.09M $1.09M
Other Current Liabilities $1.16M $1.05M $1.00M $1.00M $1.00M
Total Non-Current Liabilities $172.85M $172.21M $143.43M $146.48M $146.48M
Long Term Debt and Capital Lease Obligation $58.12M $58.18M $29.26M $31.86M $31.86M
-Long Term Debt $50.76M $50.65M $25.10M $27.52M $27.52M
-Long Term Capital Lease Obligation $7.36M $7.53M $4.16M $4.34M $4.34M
Non-Current Deferred Liabilities $18.57M $18.85M $19.12M $19.39M $19.39M
Other Non-Current Liabilities $34.97M $34.02M $32.97M $33.21M $33.21M
Total Equity -$70.82M -$56.59M -$34.05M -$33.66M -$33.66M
Stockholders' Equity -$70.82M -$56.59M -$34.05M -$33.66M -$33.66M
Capital Stock $126,000.00 $126,000.00 $124,000.00 $122,000.00 $122,000.00
-Common Stock $126,000.00 $126,000.00 $124,000.00 $122,000.00 $122,000.00
Additional Paid-In Capital $423.47M $421.21M $420.88M $413.21M $413.21M
Retained Earnings -$494.42M -$477.92M -$455.06M -$447.00M -$447.00M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$7.05M -$9.44M -$14.81M -$52.43M -$8.47M
Net cash flow from continuing operations -$7.05M -$9.44M -$14.81M -$52.43M -$8.47M
Net Income from Continuing Operations -$16.50M -$22.86M -$8.06M -$83.78M -$31.86M
Gain/Loss from Continuing Operations $0.00 – – – –
Depreciation & Depletion & Amortization $156,000.00 $136,000.00 $113,000.00 $548,000.00 $130,000.00
Other Non-Cash Items $1.46M $1.81M $3.21M $11.00M $2.75M
Change in Working Capital $5.71M -$3.10M -$12.39M $12.18M $19.14M
-Change in Receivables $4.07M -$2.46M $10.90M -$10.37M -$5.96M
-Change in Inventory $50,000.00 $706,000.00 -$1.90M -$126,000.00 $1.71M
-Change in Prepaid Assets $408,000.00 $2.14M -$340,000.00 $698,000.00 -$685,000.00
-Change in Payables and Accrued Expense $1.46M -$3.21M -$20.78M $22.56M $24.34M
-Change In Other Working Capital -$272,000.00 -$273,000.00 -$272,000.00 -$571,000.00 -$272,000.00
Net cash flow from investing -$584,000.00 -$212,000.00 -$52,000.00 -$562,000.00 -$85,000.00
Net Cash Flow from Continuing Investing Activities -$584,000.00 -$212,000.00 -$52,000.00 -$562,000.00 -$85,000.00
Capital Expenditure -$584,000.00 -$212,000.00 -$52,000.00 -$562,000.00 -$85,000.00
Financing Cash Flow -$511,000.00 -$2.59M $4.42M $102.62M $660,000.00
Net Cash Flow from Continuing Financing Activities -$511,000.00 -$2.59M $4.42M $102.62M $660,000.00
Net Issuance Payments Of Debt -$10,000.00 $5.44M -$8,000.00 -$26,000.00 $6,000.00
Net Common Stock Issuance -$27,000.00 -$79,000.00 $4.76M $100.65M -$301,000.00
Proceeds from Stock Option Exercised $177,000.00 $759,000.00 $1,000.00 $2.81M $984,000.00
Net Other Financing Charges -$651,000.00 -$8.71M -$329,000.00 -$821,000.00 -$29,000.00
Ending Cash Balance $90.35M $98.49M $110.73M $121.17M $121.17M
Net Change in Cash -$8.14M -$12.24M -$10.44M $49.62M -$7.89M
Beginning Cash Balance $98.49M $110.73M $121.17M $71.55M $129.06M
Free Cash Flow -$7.63M -$9.65M -$14.86M -$52.99M -$8.55M

Discussion

No comments yet — be the first to weigh in on AQST.

Sign in to join the discussion.

Scroll to Top